Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions

OBJECTIVES:

I. Perform a whole genome scan for association of neuroblastoma with single nucleotide
polymorphisms (SNP) and SNP haplotypes.

II. Identify true disease-associated SNP alleles using a customized genotyping platform
enriched for haplotype analyses in an independent sample set.

III. Validate disease-associated SNP alleles and haplotypes in a final independent sample
set.

IV. Identify neuroblastoma predisposition genes.

OUTLINE: This is a multicenter study. Participants are stratified according to presence of
high-risk disease (yes vs no) and MYCN amplification (yes vs no).

DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole
genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms
(SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to
identify 10-20 true disease-associated alleles. The disease-associated alleles are again
investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated
SNPs. SNPs are then analyzed for heritable predisposition.

Patients do not receive the results of the genetic testing. A certificate of confidentiality
protecting the identity of research participants in this project has been issued by the
Children's Oncology Group.

Inclusion Criteria:

- Patient:

- Diagnosis of neuroblastoma

- Banked constitutional and genomic DNA within COG-ANBL00B1 Neuroblastoma
Biology protocol or another COG Biology Protocol

- At least 1.0 ?g of DNA available

- Control (age, race, and gender-matched):

- No diagnosis of cancer

- May have other conditions, including any of the following:

- Asthma

- Inflammatory bowel disease

- Attention-deficit disorder

- Obesity